Evolocumab Approved to Prevent Cardiovascular Events

The FDA has added a new indication to evolocumab (Repatha). The PCSK9 inhibitor is now approved to prevent cardiovascular events (e.g., myocardial infarction, stroke, coronary...
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news